Need professional-grade analysis? Visit stockanalysis.com
$3.76B
14.27
N/A
N/A
Maxigen Biotech Inc (1783) trades on TW in TWD. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at TWD41.15, down 1.44% from the previous close.
Over the past year, 1783 has traded between a low of TWD41.15 and a high of TWD47.90. The stock has lost 2.1% over this period. It is currently 14.1% below its 52-week high.
Maxigen Biotech Inc has a market capitalization of $3.76B, with a price-to-earnings ratio of 14.27.
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand. In addition, the company provides collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.
Side-by-side comparison against top Healthcare peers.